Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4101 - Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer

Date

11 Sep 2017

Session

Poster display session

Presenters

Alexios Matikas

Citation

Annals of Oncology (2017) 28 (suppl_5): v68-v73. 10.1093/annonc/mdx364

Authors

A. Matikas1, J. Lövrot1, A. Ramberg2, M. Eriksson2, T. Lindsten2, T. Lekberg1, I. Hedenfalk3, N. Loman3, J. Bergh1, A. Erlandsson4, T. Hatschek1, T. Foukakis1

Author affiliations

  • 1 Oncology/pathology, Karolinska Institutet, 17176 - Stockholm/SE
  • 2 Clinical Pathology And Cytology, Central Hospital Karlstad, Karlstad/SE
  • 3 Oncology/pathology, Lund University, 223 81 - Lund/SE
  • 4 Urology, Örebro University, Örebro/SE
More

Resources

Abstract 4101

Background

Gene expression (GE) signatures and Tumor Infiltrating Lymphocyte (TILs) enumeration have shown promise as predictors of response to neoadjuvant chemotherapy in Hormone Receptor negative (HR-) and HER2+, but not in HR+/HER2- breast cancer (BC). This study aimed to explore their predictive value in HR+/HER2- BC, based on previous work from our group on the association of immune function and chemosensitivity in advanced HR+ BC.

Methods

The PROMIX phase 2 trial enrolled patients with locally advanced HER2- BC to receive six cycles of epirubicin and docetaxel, plus bevacizumab during cycles 3-6. Patients underwent tumor biopsies at baseline and after cycle 2 for GE profiling using DNA microarrays and TIL enumeration according to standard guidelines. Since pathologic complete remission (pCR) is relatively rare in HR+ BC, we also associated an immune gene module score (IMS) and TIL counts with the non-dichotomous variable of decrease in tumor size.

Results

Of the 150 enrolled patients, n = 113 were HR+. For n = 71, both TIL and GE data were available at baseline, while for n = 78 and n = 49 patients longitudinal TIL and GE data at baseline and cycle 2 were available, respectively. At baseline, on both univariate (OR = 2.29, P = 0.037) and multivariate analysis (OR = 2.35, P = 0.044) IMS was associated with pCR, while its association with tumor shrinkage was only apparent on univariate (P = 0.047) and not multivariate analysis (P = 0.061). TIL infiltration >50% (n = 9) was associated with neither pCR (OR = 1.812, P = 0.61) nor tumor shrinkage (P = 0.99). However, decreases in TIL counts in cycle 2 compared with baseline were associated with lesser decreases in tumor size (P = 0.043 for univariate and P = 0.044 for multivariate analysis).

Conclusions

Baseline immune function as assessed by GE analysis, but not TIL enumeration, and a preserved abundance of TILs after chemotherapy were predictive for chemosensitivity at the neoadjuvant setting in patients with HR+, HER2- BC.

Clinical trial identification

NCT00957125

Legal entity responsible for the study

Karolinska University Hospital

Funding

Swedish Cancer Society, BioCARE, Governmental Funding of Clinical Research within the National Health 1Service and unrestricted grants from Roche Sweden AB

Disclosure

J. Bergh: Personal fees: UpToDate. Institutional grants: AstraZeneca, Amgen, Bayer, Merck, Pfizer, Roche, Sanofi-Aventis. T. Foukakis: Personal fees: Novartis, Pfizer, Roche, UpToDate. Research institutional: Pfizer, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.